{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:24:26Z","timestamp":1790011466751,"version":"4.0.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Key Projects in the National Science and Technology Pillar Program of the 13th Five-Year Plan Period","award":["2017YFC1308300"],"award-info":[{"award-number":["2017YFC1308300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although the benefits of sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) with or without heart failure (HF), the impact of SGLT2i on cardiac remodelling remains to be established.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched the PubMed, Embase, Cochrane Library and Web of Science databases up to November 16th, 2020, for randomized controlled trials reporting the effects of SGLT2i on parameters of cardiac structure, cardiac function, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level or the Kansas City Cardiomyopathy Questionnaire (KCCQ) score in T2DM patients with or without chronic HF. The effect size was expressed as the mean difference (MD) or standardized mean difference (SMD) and its 95% confidence interval (CI). Subgroup analyses were performed based on the stage A\u2013B or stage C HF population and HF types.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared to placebo or other antidiabetic drugs, SGLT2i showed no significant effects on left ventricular mass index, left ventricular end diastolic volume index, left ventricular end systolic volume index, or left atrial volume index. SGLT2i improved left ventricular ejection fraction only in the subgroup of HF patients with reduced ejection fraction (MD 3.16%, 95% CI 0.11 to 6.22, p\u2009=\u20090.04; I<jats:sup>2<\/jats:sup>\u2009=\u20090%), and did not affect the global longitudinal strain in the overall analysis including stage A\u2013B HF patients. SGLT2i showed benefits in the E\/e\u2019 ratio (MD \u2212\u20090.45, 95% CI \u2212\u20090.88 to \u2212\u20090.03, p\u2009=\u20090.04; I<jats:sup>2<\/jats:sup>\u2009=\u20090%), plasma NT-proBNP level (SMD \u2212\u20090.09, 95% CI \u2212\u20090.16 to \u2212\u20090.03, p\u2009=\u20090.004; I<jats:sup>2<\/jats:sup>\u2009=\u20090%), and the KCCQ score (SMD 3.12, 95% CI 0.76 to 5.47, p\u00a0\u2009=\u20090.01; I<jats:sup>2<\/jats:sup>\u2009=\u20090%) in the overall population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The use of SGLT2i was associated with significant improvements in cardiac diastolic function, plasma NT-proBNP level, and the KCCQ score in T2DM patients with or without chronic HF, but did not significantly affect cardiac structural parameters indexed by body surface area. The LVEF level was improved only in HF patients with reduced ejection fraction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-020-01209-y","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T19:05:02Z","timestamp":1611601502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Effect of sodium\u2013glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Yi-Wen","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Mei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"issue":"4","key":"1209_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624\u201338.","journal-title":"Circ Res"},{"issue":"2","key":"1209_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","volume":"3","author":"A Dei Cas","year":"2015","unstructured":"Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. 2015;3(2):136\u201345.","journal-title":"JACC Heart Fail"},{"issue":"5","key":"1209_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","volume":"73","author":"K McHugh","year":"2019","unstructured":"McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, et al. Heart failure with preserved ejection fraction and diabetes: JACC State-of-the-Art review. J Am Coll Cardiol. 2019;73(5):602\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1209_CR4","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377\u201385.","journal-title":"Eur Heart J"},{"issue":"11","key":"1209_CR5","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2337\/dc17-0697","volume":"40","author":"M Dauriz","year":"2017","unstructured":"Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E, et al. Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care. 2017;40(11):1597\u2013605.","journal-title":"Diabetes Care"},{"issue":"22","key":"1209_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"21","key":"1209_CR7","first-page":"2099","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):2099.","journal-title":"N Engl J Med"},{"issue":"4","key":"1209_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"10166","key":"1209_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"key":"1209_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323:1353\u201368.","journal-title":"JAMA"},{"issue":"3","key":"1209_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","volume":"8","author":"J Zhu","year":"2020","unstructured":"Zhu J, Yu X, Zheng Y, Li J, Wang Y, Lin Y, et al. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. Lancet Diabetes Endocrinol. 2020;8(3):192\u2013205.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10254","key":"1209_CR12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020;396(10254):819\u201329.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"1209_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487\u201393.","journal-title":"Diabetes Care"},{"issue":"2","key":"1209_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ejhf.1673","volume":"22","author":"PM Seferovic","year":"2020","unstructured":"Seferovic PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, et al. European Society of Cardiology\/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2020;22(2):196\u2013213.","journal-title":"Eur J Heart Fail"},{"key":"1209_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"CG Li","year":"2019","unstructured":"Li CG, Zhang J, Xue M, Li XY, Han F, Liu XY, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18:15.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1209_CR16","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/ijms20071680","volume":"20","author":"TI Lee","year":"2019","unstructured":"Lee TI, Chen YC, Lin YK, Chung CC, Lu YY, Kao YH, et al. Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-induced diabetic rats. Int J Mol Sci. 2019;20(7):1680.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1209_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1209_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ejhf.1473","volume":"21","author":"SR Yurista","year":"2019","unstructured":"Yurista SR, Sillje HHW, Oberdorf-Maass SU, Schouten EM, Giani MGP, Hillebrands JL, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21(7):862\u201373.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"1209_CR19","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, Antonio RS, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1209_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","volume":"2","author":"NJ Byrne","year":"2017","unstructured":"Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci. 2017;2(4):347\u201354.","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"1209_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-020-0994-y","volume":"19","author":"KA Connelly","year":"2020","unstructured":"Connelly KA, Zhang Y, Desjardins JF, Nghiem L, Visram A, Batchu SN, et al. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc Diabetol. 2020;19(1):13.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1209_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","volume":"4","author":"KA Connelly","year":"2019","unstructured":"Connelly KA, Zhang Y, Visram A, Advani A, Batchu SN, Desjardins JF, et al. Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction. JACC Basic Transl Sci. 2019;4(1):27\u201337.","journal-title":"JACC Basic Transl Sci"},{"key":"1209_CR23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/eurheartj\/ehy565.P1509","volume":"39","author":"S Pabel","year":"2018","unstructured":"Pabel S, Bollenberg H, Bengel P, Tirilomis P, Mustroph J, Wagner S, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur Heart J. 2018;39:284\u20135.","journal-title":"Eur Heart J"},{"key":"1209_CR24","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","volume":"41","author":"AJM Brown","year":"2020","unstructured":"Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41:3421\u201332.","journal-title":"Eur Heart J."},{"key":"1209_CR25","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140:1693\u2013702.","journal-title":"Circulation"},{"key":"1209_CR26","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2147\/DMSO.S223629","volume":"12","author":"A Braha","year":"2019","unstructured":"Braha A, Timar B, Diaconu L, Lupusoru R, Vasiluta L, Sima A, et al. Dynamics of epicardiac fat and heart function in type 2 diabetic patients initiated with SGLT-2 inhibitors. Diabetes Metab Syndr Obes Targets Ther. 2019;12:2559\u201366.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"1","key":"1209_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12933-020-01042-3","volume":"19","author":"IC Hwang","year":"2020","unstructured":"Hwang IC, Cho GY, Yoon YE, Park JJ, Park JB, Lee SP, et al. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovasc Diabetol. 2020;19(1):69.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1209_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):73.","journal-title":"Cardiovasc Diabetol"},{"key":"1209_CR29","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.2337\/dc19-2187","volume":"43","author":"JSS Singh","year":"2020","unstructured":"Singh JSS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M, et al. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM trial. Diabetes Care. 2020;43:1356\u20139.","journal-title":"Diabetes Care"},{"key":"1209_CR30","doi-asserted-by":"publisher","first-page":"e3335","DOI":"10.1002\/dmrr.3335","volume":"36","author":"S Carbone","year":"2020","unstructured":"Carbone S, Billingsley HE, Canada JM, Bressi E, Rotelli B, Kadariya D, et al. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: results of the CANA-HF study. Diabetes\/metabolism research and reviews. 2020;36:e3335.","journal-title":"Diabetes\/metabolism research and reviews."},{"key":"1209_CR31","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/ehf2.12707","volume":"7","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Hisauchi I, Taguchi I, Sezai A, Toyoda S, Tomiyama H, et al. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE). ESC heart failure. 2020;7:1585\u201394.","journal-title":"ESC heart failure."},{"issue":"21","key":"1209_CR32","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"7","key":"1209_CR33","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/bcp.14248","volume":"86","author":"RA de Boer","year":"2020","unstructured":"de Boer RA, Nunez J, Kozlovski P, Wang Y, Proot P, Keefe D. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart failure. Br J Clin Pharmacol. 2020;86(7):1346\u201356.","journal-title":"Br J Clin Pharmacol"},{"key":"1209_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"1209_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/0962280219889080","author":"S McGrath","year":"2020","unstructured":"McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020. https:\/\/doi.org\/10.1177\/0962280219889080.","journal-title":"Stat Methods Med Res"},{"key":"1209_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"1209_CR37","unstructured":"JPT H, (editors) GS. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http:\/\/www.cochrane-handbook.org."},{"issue":"29","key":"1209_CR38","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1002\/sim.3427","volume":"27","author":"JP Higgins","year":"2008","unstructured":"Higgins JP, White IR, Anzures-Cabrera J. Meta-analysis of skewed data: combining results reported on log-transformed or raw scales. Stat Med. 2008;27(29):6072\u201392.","journal-title":"Stat Med"},{"issue":"9","key":"1209_CR39","doi-asserted-by":"publisher","first-page":"e015716","DOI":"10.1161\/JAHA.119.015716","volume":"9","author":"I Ikonomidis","year":"2020","unstructured":"Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, et al. Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment. J Am Heart Assoc. 2020;9(9):e015716.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1209_CR40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12933-019-0910-5","volume":"18","author":"BM Bonora","year":"2019","unstructured":"Bonora BM, de Kreutzenberg SV, Avogaro A, Fadini GP. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes Secondary analysis of a randomized placebo-controlled trial. Cardiovasc Diabetol. 2019;18(1):106.","journal-title":"Cardiovasc Diabetol"},{"key":"1209_CR41","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","volume":"142","author":"M Griffin","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in heart failure: diuretic and cardio-renal effects. Circulation. 2020;142:1028\u201339.","journal-title":"Circulation"},{"key":"1209_CR42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051824","author":"SD Anker","year":"2020","unstructured":"Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status\u2014results from the EMPEROR-reduced trial. Circulation. 2020. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051824.","journal-title":"Circulation"},{"key":"1209_CR43","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2020.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa2030183.","DOI":"10.1056\/NEJMoa2030183"},{"issue":"7","key":"1209_CR44","doi-asserted-by":"publisher","first-page":"107590","DOI":"10.1016\/j.jdiacomp.2020.107590","volume":"34","author":"MK Eickhoff","year":"2020","unstructured":"Eickhoff MK, Olsen FJ, Frimodt-Moller M, Diaz LJ, Faber J, Jensen MT, et al. Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria\u2014a double blind randomized placebo-controlled crossover trial. J Diabetes Complications. 2020;34(7):107590.","journal-title":"J Diabetes Complications"},{"issue":"16","key":"1209_CR45","doi-asserted-by":"publisher","first-page":"e015103","DOI":"10.1161\/JAHA.119.015103","volume":"9","author":"K Ejiri","year":"2020","unstructured":"Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, et al. Effect of luseogliflozin on heart failure with preserved ejection fraction in patients with diabetes mellitus. J Am Heart Assoc. 2020;9(16):e015103.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"1209_CR46","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","volume":"70","author":"JL Januzzi Jr","year":"2017","unstructured":"Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70(6):704\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1209_CR47","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.jacc.2020.09.004","volume":"76","author":"JL Januzzi Jr","year":"2020","unstructured":"Januzzi JL Jr, Xu J, Li J, Shaw W, Oh R, Pfeifer M, et al. Effects of canagliflozin on amino-terminal pro-b-type natriuretic peptide: implications for cardiovascular risk reduction. J Am Coll Cardiol. 2020;76(18):2076\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1209_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-020-01079-4","volume":"19","author":"N Katakami","year":"2020","unstructured":"Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol. 2020;19(1):1\u201316.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"1209_CR49","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1253\/circj.CJ-20-0341","volume":"84","author":"H Kayano","year":"2020","unstructured":"Kayano H, Koba S, Hirano T, Matsui T, Fukuoka H, Tsuijita H, et al. Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients\u2014a randomized controlled trial. Circ J. 2020;84(10):1807\u201317.","journal-title":"Circ J"},{"issue":"18","key":"1209_CR50","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","volume":"142","author":"NA Mordi","year":"2020","unstructured":"Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the recede-chf trial. Circulation. 2020;142(18):1713\u201324.","journal-title":"Circulation"},{"issue":"SUPPL 1","key":"1209_CR51","first-page":"S62","volume":"63","author":"J Oldgren","year":"2020","unstructured":"Oldgren J, Laurila S, Akerblom A, Latva-Rasku A, Rebelos E, Isackson H, et al. Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes. Diabetologia. 2020;63(SUPPL 1):S62\u20133.","journal-title":"Diabetologia"},{"key":"1209_CR52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051992","author":"CY Shim","year":"2020","unstructured":"Shim CY, Seo J, Cho I, Lee CJ, Cho IJ, Lhagvasuren P, et al. Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus: the IDDIA trial. Circulation. 2020. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051992.","journal-title":"Circulation"},{"key":"1209_CR53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.amjcard.2020.08.002","volume":"134","author":"D Patoulias","year":"2020","unstructured":"Patoulias D, Papadopoulos C, Katsimardou A, Kalogirou M-S, Doumas M. Meta-analysis assessing the effect of sodium-glucose co-transporter-2 inhibitors on left ventricular mass in patients with type 2 diabetes mellitus. Am J Cardiol. 2020;134:149\u201352.","journal-title":"Am J Cardiol"},{"issue":"11","key":"1209_CR54","doi-asserted-by":"publisher","first-page":"e0166125","DOI":"10.1371\/journal.pone.0166125","volume":"11","author":"H Storgaard","year":"2016","unstructured":"Storgaard H, Gluud LL, Bennett C, Gr\u00f8ndahl MF, Christensen MB, Knop FK, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2016;11(11):e0166125.","journal-title":"PLoS ONE"},{"issue":"12","key":"1209_CR55","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1016\/j.jacc.2003.11.064","volume":"43","author":"MH Drazner","year":"2004","unstructured":"Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43(12):2207\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1209_CR56","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","volume":"322","author":"D Levy","year":"1990","unstructured":"Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561\u20136.","journal-title":"N Engl J Med"},{"issue":"12","key":"1209_CR57","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jcmg.2015.07.013","volume":"8","author":"M Sengel\u00f8v","year":"2015","unstructured":"Sengel\u00f8v M, J\u00f8rgensen PG, Jensen JS, Bruun NE, Olsen FJ, Fritz-Hansen T, et al. Global longitudinal strain is a superior predictor of all-cause mortality in heart failure with reduced ejection fraction. JACC Cardiovasc Imaging. 2015;8(12):1351\u20139.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"1209_CR58","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jacc.2013.09.052","volume":"63","author":"E Kraigher-Krainer","year":"2014","unstructured":"Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(5):447\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"1209_CR59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12933-016-0333-5","volume":"15","author":"JH Liu","year":"2016","unstructured":"Liu JH, Chen Y, Yuen M, Zhen Z, Chan CW, Lam KS, et al. Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016;15:22.","journal-title":"Cardiovasc Diabetol"},{"issue":"18","key":"1209_CR60","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.jacc.2020.09.538","volume":"76","author":"EJ Velazquez","year":"2020","unstructured":"Velazquez EJ, Reinhardt SW. Limitations of natriuretic peptide levels in establishing SGLT-2 inhibitors for heart failure care. J Am Coll Cardiol. 2020;76(18):2086\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1209_CR61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jchf.2013.11.007","volume":"2","author":"G Savarese","year":"2014","unstructured":"Savarese G, Musella F, D\u2019Amore C, Vassallo E, Losco T, Gambardella F, et al. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart failure. 2014;2(2):148\u201358.","journal-title":"JACC Heart failure"},{"issue":"22","key":"1209_CR62","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","volume":"68","author":"MR Zile","year":"2016","unstructured":"Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, et al. Prognostic implications of changes in n-terminal pro-b-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016;68(22):2425\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1209_CR63","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","volume":"8","author":"JW Cunningham","year":"2020","unstructured":"Cunningham JW, Vaduganathan M, Claggett BL, Zile MR, Anand IS, Packer M, et al. Effects of sacubitril\/valsartan on N-terminal Pro-B-type natriuretic peptide in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8(5):372\u201381.","journal-title":"JACC Heart Fail"},{"issue":"8","key":"1209_CR64","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jama.2017.10565","volume":"318","author":"GM Felker","year":"2017","unstructured":"Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017;318(8):713\u201320.","journal-title":"JAMA"},{"issue":"20","key":"1209_CR65","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","volume":"76","author":"JA Spertus","year":"2020","unstructured":"Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas city cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art Review. J Am Coll Cardiol. 2020;76(20):2379\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1209_CR66","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.pcad.2019.07.005","volume":"62","author":"V Garg","year":"2019","unstructured":"Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis. 2019;62(4):349\u201357.","journal-title":"Prog Cardiovasc Dis"},{"issue":"12","key":"1209_CR67","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.117.029529","volume":"136","author":"K Striepe","year":"2017","unstructured":"Striepe K, Jumar A, Ott C, Karg MV, Schneider MP, Kannenkeril D, et al. Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus. Circulation. 2017;136(12):1167\u20139.","journal-title":"Circulation"},{"issue":"7","key":"1209_CR68","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME Trial: a \u201cThrifty Substrate\u201d hypothesis. Diabetes Care. 2016;39(7):1108\u201314.","journal-title":"Diabetes Care"},{"key":"1209_CR69","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","volume":"85","author":"WT Garvey","year":"2018","unstructured":"Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metab Clin Exp. 2018;85:32\u20137.","journal-title":"Metab Clin Exp"},{"issue":"1","key":"1209_CR70","doi-asserted-by":"publisher","first-page":"e006277","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","volume":"13","author":"NJ Byrne","year":"2020","unstructured":"Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, et al. Empagliflozin Blunts worsening cardiac dysfunction associated with reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13(1):e006277.","journal-title":"Circ Heart Fail"},{"key":"1209_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa323","author":"YJ Chung","year":"2020","unstructured":"Chung YJ, Park KC, Tokar S, Eykyn TR, Fuller W, Pavlovic D, et al. Off-target effects of SGLT2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res. 2020. https:\/\/doi.org\/10.1093\/cvr\/cvaa323.","journal-title":"Cardiovasc Res"},{"key":"1209_CR72","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1016\/j.amjmed.2020.04.006","volume":"133","author":"K Kumar","year":"2020","unstructured":"Kumar K, Kheiri B, Simpson TF, Osman M, Rahmouni H. Sodium-glucose cotransporter 2 inhibitors in heart failure: a meta-analysis of randomized clinical trials. Am J Med. 2020;133:e625\u201330.","journal-title":"Am J Med"},{"issue":"1","key":"1209_CR73","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12947-019-0177-8","volume":"17","author":"K Matsumura","year":"2019","unstructured":"Matsumura K, Sugiura T. Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review. Cardiovasc Ultrasound. 2019;17(1):26.","journal-title":"Cardiovasc Ultrasound"},{"issue":"5","key":"1209_CR74","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ehf2.12505","volume":"6","author":"NSR Lan","year":"2019","unstructured":"Lan NSR, Fegan PG, Yeap BB, Dwivedi G. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019;6(5):927\u201335.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"1209_CR75","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10741-018-9668-1","volume":"23","author":"H Tanaka","year":"2018","unstructured":"Tanaka H, Hirata KI. Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus. Heart Fail Rev. 2018;23(3):439\u201344.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"1209_CR76","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10557-018-06850-0","volume":"33","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, et al. Rationale and design of the EMPA-TROPISM Trial (ATRU-4): are the \u201cCardiac Benefits\u201d of empagliflozin independent of its hypoglycemic activity? Cardiovasc Drugs Ther. 2019;33(1):87\u201395.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"1209_CR77","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-017-0615-6","volume":"16","author":"A Natali","year":"2017","unstructured":"Natali A, Nesti L, Fabiani I, Calogero E, Di Bello V. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovasc Diabetol. 2017;16(1):130.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1209_CR78","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/ejhf.1486","volume":"21","author":"WT Abraham","year":"2019","unstructured":"Abraham WT, Ponikowski P, Brueckmann M, Zeller C, Macesic H, Peil B, et al. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. Eur J Heart Fail. 2019;21(7):932\u201342.","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01209-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01209-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01209-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T15:03:39Z","timestamp":1674918219000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01209-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01209-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"9 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}